cilostazol has been researched along with Albuminuria in 6 studies
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients." | 9.14 | The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009) |
| "Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties." | 6.79 | Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. ( Hsiao, FC; Hsieh, CH; Hung, YJ; Kuo, FC; Lee, CH; Lin, FH; Tang, WH, 2014) |
| "We evaluated association between hyperinsulinemia/insulin resistance and microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 5.32 | Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. ( Oshiro, Y; Shimabukuro, M; Shimajiri, Y; Takasu, N; Tohma, T; Yamakawa, M, 2004) |
| "Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia-reperfusion injury, in PAD patients." | 5.14 | The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease. ( Badger, SA; Lee, B; Makar, RR; McEneny, J; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009) |
| "Cilostazol is an antiplatelet, antithrombotic agent with anti-inflammatory properties." | 2.79 | Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial. ( Hsiao, FC; Hsieh, CH; Hung, YJ; Kuo, FC; Lee, CH; Lin, FH; Tang, WH, 2014) |
| "We evaluated association between hyperinsulinemia/insulin resistance and microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty (OLETF) rat." | 1.32 | Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat. ( Oshiro, Y; Shimabukuro, M; Shimajiri, Y; Takasu, N; Tohma, T; Yamakawa, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, WH | 1 |
| Lin, FH | 1 |
| Lee, CH | 1 |
| Kuo, FC | 1 |
| Hsieh, CH | 1 |
| Hsiao, FC | 1 |
| Hung, YJ | 1 |
| Jiao, XM | 1 |
| Jiao, XJ | 1 |
| Zhang, XG | 1 |
| Xu, XP | 1 |
| Wu, JX | 1 |
| Yao, L | 1 |
| Zhao, J | 1 |
| Lü, XF | 1 |
| He, P | 1 |
| Kawamura, H | 1 |
| Takemoto, M | 1 |
| Maezawa, Y | 1 |
| Ishikawa, T | 1 |
| Ishibashi, R | 1 |
| Sakamoto, K | 1 |
| Shoji, M | 1 |
| Hattori, A | 1 |
| Yamaga, M | 1 |
| Ide, S | 1 |
| Ide, K | 1 |
| Hayashi, A | 1 |
| Tokuyama, H | 1 |
| Kobayashi, K | 1 |
| Yokote, K | 1 |
| Park, JH | 1 |
| Choi, BH | 1 |
| Ku, SK | 1 |
| Kim, DH | 1 |
| Jung, KA | 1 |
| Oh, E | 1 |
| Kwak, MK | 1 |
| O'Donnell, ME | 1 |
| Badger, SA | 1 |
| Sharif, MA | 1 |
| Makar, RR | 1 |
| McEneny, J | 1 |
| Young, IS | 1 |
| Lee, B | 1 |
| Soong, CV | 1 |
| Tohma, T | 1 |
| Shimabukuro, M | 1 |
| Oshiro, Y | 1 |
| Yamakawa, M | 1 |
| Shimajiri, Y | 1 |
| Takasu, N | 1 |
3 trials available for cilostazol and Albuminuria
| Article | Year |
|---|---|
Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Albuminuria; Anti-Inflammatory Agents; Chemokine CCL2; Cil | 2014 |
Cilostazol reduces microalbuminuria in type 2 diabetic nephropathy.
Topics: Albuminuria; Cilostazol; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Tetrazoles | 2013 |
The effects of cilostazol on exercise-induced ischaemia-reperfusion injury in patients with peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; alpha-Tocopherol; Ascorbate Oxidase; beta Carotene; C-R | 2009 |
3 other studies available for cilostazol and Albuminuria
| Article | Year |
|---|---|
Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms.
Topics: Albuminuria; Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Chemokine CCL2; Cilos | 2017 |
Amelioration of high fat diet-induced nephropathy by cilostazol and rosuvastatin.
Topics: Albuminuria; Animals; Anti-Bacterial Agents; Cilostazol; Cystatin C; Diet, High-Fat; Heme Oxygenase- | 2017 |
Cilostazol, a phosphodiesterase inhibitor, reduces microalbuminuria in the insulin-resistant Otsuka Long-Evans Tokushima Fatty rat.
Topics: Albuminuria; Animals; Blood Glucose; Cilostazol; Collagen Type I; Diabetic Nephropathies; Fibronecti | 2004 |